Gland Pharma Q2 Results Live: Profit Falls by 15.74% YOY
Gland Pharma Q2 Results Live: Revenue increased by 2.36% YoY & profit decreased by 15.74% YoY.
Gland Pharma Q2 Results Live : Gland Pharma declared their Q2 results on 04 Nov, 2024, reporting a topline increase of 2.36% year-over-year, while profit saw a significant decline of 15.74%. Compared to the previous quarter, revenue grew by 0.29%, and profit increased by 13.75%.
The company's selling, general, and administrative expenses showed a decline of 6.68% quarter-over-quarter, although they increased by 3.29% year-over-year. This fluctuation highlights the challenges Gland Pharma faces in managing costs amidst changing market conditions.
Operating income experienced a notable increase of 17.86% quarter-over-quarter but fell by 16.29% compared to the same period last year. This divergence suggests that while the company is improving its short-term operational efficiency, it is struggling to maintain long-term profitability.
Earnings per share (EPS) for Q2 stood at ₹9.93, marking a decrease of 15.7% year-over-year. This drop in EPS reflects the overall decline in profitability that Gland Pharma is currently experiencing.
In terms of stock performance, Gland Pharma has delivered a return of -0.84% over the last week, -5.42% over the past six months, and -16.3% year-to-date. These figures indicate a challenging market environment for the company, affecting investor sentiment.
As of now, Gland Pharma has a market capitalization of ₹26,539.86 crore, with a 52-week high of ₹2,220.95 and a low of ₹1,509.30. These metrics suggest a volatile trading period for the company's shares.
Analyst opinions are mixed, with 2 out of 10 analysts giving a Strong Sell rating, 4 recommending Sell, 1 suggesting Hold, and 3 advocating for Strong Buy. The consensus recommendation as of 05 Nov, 2024, was to Hold, indicating cautious optimism among some market experts.
Gland Pharma Financials
| Period | Q2 | Q1 | Q-o-Q Growth | Q2 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 1405.83 | 1401.71 | +0.29% | 1373.42 | +2.36% |
| Selling/ General/ Admin Expenses Total | 375.19 | 402.04 | -6.68% | 363.23 | +3.29% |
| Depreciation/ Amortization | 93.83 | 91.96 | +2.03% | 81.3 | +15.41% |
| Total Operating Expense | 1202.6 | 1229.28 | -2.17% | 1130.64 | +6.36% |
| Operating Income | 203.23 | 172.44 | +17.86% | 242.78 | -16.29% |
| Net Income Before Taxes | 256.78 | 218.24 | +17.66% | 289.89 | -11.42% |
| Net Income | 163.53 | 143.76 | +13.75% | 194.08 | -15.74% |
| Diluted Normalized EPS | 9.93 | 8.73 | +13.75% | 11.78 | -15.7% |
Stay updated on quarterly results with our results calendar
Catch all the Business News , Corporate news , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
MoreLess
FAQs
₹163.53Cr
₹1405.83Cr
First Published:5 Nov 2024, 11:58 AM IST
- Top Gainers
- Top Losers
- 52 Week High